Physician profile
Aric Blom
NPI 1114905411
$1,678.17
in general payments reported to CMS, 2019-2025
22 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.99 · 2022: $52.55 · 2023: $197 · 2024: $1,041 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $367.35 | 2022-2025 | |
| Astellas Pharma US INC | $187.12 | 2023-2025 | Xtandi, Padcev, Xospata |
| Pfizer INC. | $133.05 | 2024-2025 | |
| Springworks Therapeutics, INC. | $120.70 | 2024-2025 | Ogsiveo |
| Astrazeneca Pharmaceuticals Lp | $116.19 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Lilly USA, LLC | $76.81 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $74.45 | 2022-2023 | Tivdak, Padcev |
| Merck Sharp & Dohme LLC | $73.90 | 2024 | Keytruda, Welireg |
| Glaxosmithkline, LLC. | $61.58 | 2024-2025 | Jemperli, Zejula |
| Janssen Biotech, INC. | $60.61 | 2024 | Rybrevant |
| Amgen INC. | $55.10 | 2022-2024 | Imdelltra (Amg 757) |
| Gilead Sciences, INC. | $54.20 | 2024-2025 | Trodelvy |
| Daiichi Sankyo INC. | $49.33 | 2021-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $44.23 | 2024-2025 | Opdivo |
| Servier Pharmaceuticals LLC | $42.29 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $27.83 | 2024 | |
| Eisai INC. | $24.49 | 2023 | |
| Array Biopharma INC | $23.21 | 2024 | Mektovi, Braftovi, Xalkori |
| Blueprint Medicines Corporation | $22.36 | 2024 | |
| Sobi, INC | $22.34 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.19 | 2024 | Fruzaqla |
| Collegium Pharmaceutical, INC. | $18.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aric Blom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.